(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
(Alliance News) - Creo Medical Group PLC on Wednesday said that cost controls and new product sales had supported strong growth in 2023, as the company said it is on track to achieve cash flow break-even by 2025. Read More
Creo Medical Group PLC - Chepstow, Wales-based medical device company focused on surgical endoscopy - Will collaborate with Khalifa University of Science & Technology in Abu Dhabi. Says partnership has an initial focus on healthcare challenges relevant to the population in the United Arab Emirates, as well as the wider Middle East and North Africa region. Chief Executive Officer Craig Gulliford says: "As part of our strategy, we are driven to exploit our IP either directly or in partnership with third-parties, as shown by our robotic assisted surgery collaborations. Khalifa University is a research-intensive organisation with a similar drive to develop and commercially exploit leading technologies, at scale and on a global basis. The combination of Creo's people, technology and IP with Khalifa University's teams, technologies, facilities and resources represents a great opportunity for both organisations to advance and commercialise incremental technology and products and enhance research profiles internationally." Read More
(Alliance News) - The following is a round-up of trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - Creo Medical Group PLC on Wednesday said its Speedboat UltraSlim device has been used successfully in Latin America for the first time. Read More
Creo Medical Group PLC - Chepstow, Wales-based medical device company focused on surgical endoscopy - Says SpeedBoat UltraSlim device has been successfully used in the US across multiple clinical applications. SpeedBoat UltraSlim is third brand in its Speedboat family of devices alongside Speedboat Inject and offers a number of different features.This primarily includes the reduced size in comparison with the Speedboat Inject, Creo Medical said, making the device compatible with all endoscopes with a 2.8 millimetre working channel or larger. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - Creo Medical Group PLC on Wednesday said the EU launch of its SpeedBoat UltraSlim device has been accelerated by around 18 months ahead of schedule. Read More
(Alliance News) - Creo Medical Group PLC on Tuesday reported a narrowed interim loss amid higher revenue. Read More
(Alliance News) - Creo Medical Group PLC on Wednesday said the Royal Oldham hospital in Greater Manchester has now treated over 40 patients with two of Creo Medical's technologies. Read More
(Alliance News) - Creo Medical PLC said it expects to report a boost in revenue and a decrease in its administrative expenses in its half year. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - Creo Medical Group PLC on Monday said the first upper gastrointestinal tract using the Speedboat Inject procedure has been completed in Europe since its clearance last week. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday. Read More
(Alliance News) - Stocks in London ended lower on Monday, weighed down by a disappointing post-Covid recovery in China and the increasing expectation that interest rates in the UK will keep pushing higher. Read More
Creo Medical Group PLC - Chepstow, Wales-based medical device company focused on surgical endoscopy - Says its Speedboat Inject endoscopy product has been cleared for use in the entire gastrointestinal tract within European markets. Speedboat Inject is already cleared for full use in the gastrointestinal tract for the cutting and coagulation of soft tissue using radio frequency and microwave energy in the US and Asia Pacific regions. It is used for the prevention and treatment of bowel cancer. Adds it already has a "healthy pipeline" of clinicians ready to use the Speedboat Inject device for upper gastrointestinal procedures across Europe, with demonstrations, training and procedures already planned. Read More
(Alliance News) - Creo Medical Group PLC on Thursday said the National Institute for Health & Care Excellence in the UK has selected its Speedboat Inject product for assessment. Read More
(Alliance News) - Creo Medical Group PLC on Tuesday said that it has reached its first in-human milestone for MicroBlate Flex, as part of a Lung Tissue ablation clinical study. Read More